Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) is a precision oncology diagnostics company specializing in comprehensive genomic profiling (CGP) solutions for solid tumors. The company offers kitted genomic testing platforms designed to democratize access to cancer genomics in distributed laboratory settings worldwide. PGDx manufactures FDA-cleared and CE-IVD marked tissue and plasma-based assays that enable rapid, actionable genomic insights without requiring centralized laboratory infrastructure. The PGDx elio tissue complete test profiles 500+ solid tumor-related genes with somatic mutation identification including SNVs, indels, tumor mutational burden (TMB), microsatellite instability (MSI), and select amplifications and translocations. The PGDx elio plasma complete assay is a liquid biopsy solution analyzing circulating tumor DNA for biomarker discovery across pan-solid tumors, eliminating the need for invasive tissue sampling. Both platforms integrate proprietary bioinformatics for fully automated data analysis and clinical reporting. The company supports early-stage and late-stage biopharma services including biomarker discovery, companion diagnostic (CDx) development, and translational research. PGDx is now part of the LabCorp network, enhancing service delivery and clinical laboratory partnerships globally. Products are backed by turn-key bioinformatics enabling in-house testing and local control of genomic data.